Evidence map›Paper›PMID 39644020›Full record

ReviewHematology. American Society of Hematology. Education Program2024

Molecular landscape and classification of vascular anomalies.

Emmanuel Seront, Angela Queisser, Laurence M Boon, Miikka Vikkula

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hematology. American Society of Hematology. Education Program, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Emmanuel SerontCenter for Vascular Anomalies (a VASCERN VASCA European Reference Centre), Institut Roi Albert II, Department of Medical Oncology, Cliniques universitaires St Luc, University of Louvain, Brussels, Belgium.
Angela QueisserCenter for Vascular Anomalies (a VASCERN VASCA European Reference Centre), Human Molecular Genetics, de Duve Institute, University of Louvain, Brussels, Belgium.
Laurence M BoonCenter for Vascular Anomalies (a VASCERN VASCA European Reference Centre), Division of Plastic Surgery, Cliniques universitaires St Luc, University of Louvain, Brussels, Belgium.
Miikka VikkulaCenter for Vascular Anomalies (a VASCERN VASCA European Reference Centre), Human Molecular Genetics, de Duve Institute, University of Louvain, Brussels, Belgium.

Funding

Blood vessel assembly from multipotent hemangioma-derived stem cellsR01HL096384 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI Joyce E. Bischoff · 2009 to 2026
$7.7M
NHLBI NIH HHS R01 HL096384
6 · The paper itself

Abstract

Vascular malformations, which result from anomalies in angiogenesis, include capillary, lymphatic, venous, arteriovenous, and mixed malformations and affect specific vessel types. Historically, treatments such as sclerotherapy and surgery have shown limited efficacy in complicated cases. Most vascular malformations occur sporadically, but some can be inherited. They result from mutations similar to oncogenic alterations, activating pathways such as PI3K-AKT-mTOR or Ras-MAPK-ERK. Recognizing these parallels, we highlight the potential of targeted molecular inhibitors, repurposing anticancer drugs for the treatment of vascular malformations. This case-based review explores recent developments in precision medicine for slow-flow and fast-flow vascular malformation.

Indexed as

Vascular MalformationsFemaleHumansMaleMutation

Identifiers

PMID39644020
PMCPMC11665640

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.